Progressive Familial Intrahepatic Cholestasis
FDA expands Livmarli approval for pruritus in PFIC to infants as young as 12 months
The FDA has updated the label indication for Livmarli for the treatment of cholestatic pruritus in patients with progressive familial intrahepatic cholestasis, expanding the patient population to include infants aged 12 months and older.
Maralixibat improves pruritis, reduces total serum bile acids in all PFIC subtypes
Maralixibat improved cholestatic pruritis and reduced serum bile acids in pediatric patients with progressive familial intrahepatic cholestasis, regardless of disease genotype, according to data from the MARCH-PFIC trial.
FDA approves Livmarli for pruritus in progressive familial intrahepatic cholestasis
The FDA has approved Mirum Pharmaceuticals’ Livmarli oral solution for treatment of cholestatic pruritus in patients aged 5 years and older with progressive familial intrahepatic cholestasis, according to a company release.
VIDEO: Treatment with Livmarli yields ‘broad base effects’ across range of PFIC types
BOSTON — In a Healio video exclusive, Pam Vig, PhD, reports late-breaking data that show Livmarli improved liver health and maintained symptom response over 2 years among pediatric patients with progressive familial cholestasis.
VIDEO: Livmarli reduces serum bile acids and pruritus in PFIC, Alagille syndrome
In a Healio video exclusive, Pam Vig, PhD, highlights new data on Livmarli for the treatment of patients with pruritus due to progressive familial intrahepatic cholestasis and Alagille syndrome, which were presented at EASL Congress.
VIDEO: Progressive familial intrahepatic cholestasis improves with use of novel agent
In a video exclusive, Lorenzo D’Antiga, MD, Pappa Giovanni XXIII Hospital, said Bylvay induced a sustained improvement in cholestasis-related parameters in patients with progressive familial intrahepatic cholestasis.